Astellas Experiments With Partnering Models For a Phase IIa Ulcerative Colitis Compound
This article was originally published in PharmAsia News
Executive Summary
Astellas out-licensed a melanocortin receptor agonist to a virtual company backed by Astellas' corporate venture arm.